OncRef

Clinical Trial: NCT00719888

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Fred Hutchinson Cancer Center
Information Provided By:Fred Hutchinson Cancer Center
Last Update Posted:2025-03-07

Study Overview

Brief Summary

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.

Official Title

Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen

Conditions

Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma

Intervention / Treatment

  • Drug: Cyclophosphamide
  • Drug: Cyclosporine
  • Procedure: Double-Unit Umbilical Cord Blood Transplantation
  • Drug: Fludarabine
  • Other: Laboratory Biomarker Analysis
  • Drug: Mycophenolate Mofetil
  • Radiation: Total-Body Irradiation
  • Procedure: Umbilical Cord Blood Transplantation
  • Drug: Thiotepa

Other Study ID Numbers

  • 2010.00
  • NCI-2010-00190
  • 2010
  • RG2807002

Start Date (Actual)

2005-11-18

Primary Completion Date (Actual)

2023-12-22

Study Completion Date (Actual)

2024-12-19

Enrollment (Actual)

135

Study Type

Interventional

Phase

Phase 2